1. Epidemiology and Global Health
  2. Microbiology and Infectious Disease

Systematic screening of viral and human genetic variation identifies antiretroviral resistance and immune escape link

  1. Huyen Nguyen  Is a corresponding author
  2. Christian Wandell Thorball
  3. Jacques Fellay
  4. Jürg Böni
  5. Sabine Yerly
  6. Matthieu Perreau
  7. Hans H Hirsch
  8. Katharina Kusejko
  9. Maria Christine Thurnheer
  10. Manuel Battegay
  11. Matthias Cavassini
  12. Christian R Kahlert
  13. Enos Bernasconi
  14. Huldrych F Günthard
  15. Roger D Kouyos  Is a corresponding author
  16. The Swiss HIV Cohort Study
  1. Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Switzerland
  2. Institute of Medical Virology, Swiss National Center for Retroviruses, University of Zurich, Switzerland
  3. School of Life Sciences, École Polytechnique, Switzerland
  4. Precision Medicine Unit, Lausanne University Hospital and University of Lausanne, Switzerland
  5. Laboratory of Virology, Geneva University Hospital, University of Geneva, Switzerland
  6. Division of Immunology and Allergy, University Hospital Lausanne, University of Lausanne, Switzerland
  7. Transplantation & Clinical Virology, Department of Biomedicine, University of Basel, Switzerland
  8. Infectious Diseases and Hospital Epidemiology, Department of Medicine, University Hospital Basel, Switzerland
  9. Clinical Virology, Laboratory Medicine, University Hospital Basel, Switzerland
  10. University Clinic of Infectious Diseases, University Hospital of Bern, University of Bern, Switzerland
  11. Department of Infectious Diseases, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Switzerland
  12. Division of Infectious Diseases and Hospital Epidemiology, Kantonsspital St. Gallen, Switzerland
  13. Division of Infectious Diseases, Regional Hospital, Switzerland
https://doi.org/10.7554/eLife.67388
Share this article
Cite this article
  1. Huyen Nguyen
  2. Christian Wandell Thorball
  3. Jacques Fellay
  4. Jürg Böni
  5. Sabine Yerly
  6. Matthieu Perreau
  7. Hans H Hirsch
  8. Katharina Kusejko
  9. Maria Christine Thurnheer
  10. Manuel Battegay
  11. Matthias Cavassini
  12. Christian R Kahlert
  13. Enos Bernasconi
  14. Huldrych F Günthard
  15. Roger D Kouyos
  16. The Swiss HIV Cohort Study
(2021)
Systematic screening of viral and human genetic variation identifies antiretroviral resistance and immune escape link
eLife 10:e67388.
https://doi.org/10.7554/eLife.67388
  2. Download BibTeX
  3. Download .RIS

Abstract

Background:

Considering the remaining threat of drug-resistantmutations (DRMs) to antiretroviral treatment (ART) efficacy, we investigated how the selective pressure of human leukocyte antigen (HLA)-restricted cytotoxic T lymphocytes drives certain DRMs’ emergence and retention.

Methods:

We systematically screened DRM:HLA class I allele combinations in 3997 ART-naïve Swiss HIV Cohort Study (SHCS) patients. For each pair, a logistic regression model preliminarily tested for an association with the DRM as the outcome. The three HLA:DRM pairs remaining after multiple testing adjustment were analyzed in three ways: cross-sectional logistic regression models to determine any HLA/infection time interaction, survival analyses to examine if HLA type correlated with developing specific DRMs, and via NetMHCpan to find epitope binding evidence of immune escape.

Results:

Only one pair, RT-E138:HLA-B18, exhibited a significant interaction between infection duration and HLA. The survival analyses predicted two pairs with an increased hazard of developing DRMs: RT-E138:HLA-B18 and RT-V179:HLA-B35. RT-E138:HLA-B18 exhibited the greatest significance in both analyses (interaction term odds ratio [OR] 1.169 [95% confidence interval (CI) 1.075–1.273]; p-value<0.001; survival hazard ratio 12.211 [95% CI 3.523–42.318]; p-value<0.001). The same two pairs were also predicted by netMHCpan to have epitopic binding.

Conclusions:

We identified DRM:HLA pairs where HLA presence is associated with the presence or emergence of the DRM, indicating that the selective pressure for these mutations alternates direction depending on the presence of these HLA alleles.

Funding:

Funded by the Swiss National Science Foundation within the framework of the SHCS, and the University of Zurich, University Research Priority Program: Evolution in Action: From Genomes Ecosystems, in Switzerland.

Introduction

Antiretroviral resistance remains a major obstacle to the successful and lasting suppression of HIV (Gupta et al., 2012; Günthard et al., 2019). While in resource-rich settings the availability of novel drug classes and personalized HIV treatment have diminished the challenges associated with antiretroviral resistance, resource-limited settings have experienced a continuous increase in antiretroviral resistance, which is now threatening the unprecedented success of the global rollout of antiretroviral treatment (ART) (Fund, 2019; Hauser et al., 2019). In the context of this globalization of antiretroviral resistance, it is becoming increasingly important to understand how human and viral genetic variation are affecting the processes generating or limiting antiretroviral resistance (Aghokeng et al., 2011; Lataillade et al., 2010).

HIV drug-resistant mutations (DRMs) can either be selected in patients on ART experiencing treatment failure (acquired drug resistance, or aDRM) or be transmitted from a patient carrying the resistance mutation to an uninfected individual (transmitted drug resistance, tDRM). As some DRMs have been shown to carry a cost, feeding on the virus fitness and replication capacity, they can revert in the absence of ART. Once the selective pressure favoring those mutations is removed, their frequency within a host continuously decreases at the expense of the wild-type variant, and eventually they become undetectable by standard resistance tests. It has been shown that the time scales on which reversion occurs exhibit a large variation ranging from several months to over 10 years, depending on the fitness cost that in turn is governed by both the type of mutation and the genetic background in which it occurs (Kühnert et al., 2018; Yang et al., 2015). This canonical perspective based on the evolutionary forces of aDRM and tDRM, and their disappearance from the replicating quasi-species, generally disregards the possibility that antiretroviral- resistant mutations are selected in untreated individuals.

One process that may act against the paradigm of DRM emerging only in treated individuals and reverting in untreated individuals is accidental resistance evolution occurring as a collateral effect of viral immune escape. A well-understood instance of this process is evolutionary escape from binding to human leukocyte antigen (HLA), an extremely diverse gene complex encoding for major histocompatibility complex (MHC) proteins. MHC class I proteins (corresponding to HLA class I) are found on the surface of all nucleated cells, and by presenting antigens from the cell interior to the surface, they allow for binding to cytotoxic CD8 T cells (CTL); thus, MHC class I proteins tag the virally infected cell and can subsequently be eliminated by CTL (Markov and Pybus, 2015; Zinkernagel and Doherty, 1979). The high mutation rate associated with replicating HIV predisposes to cellular and humoral immune escape, where the viral epitopes are no longer recognized by the mounted immune effectors. For CTL-mediated immune responses, this process of developing escape mutations remains a critical part of HIV pathogenesis (Leslie et al., 2004). Conversely, the high variability of encoded MHC alleles and their combinations come into play, as the host HLA alleles change as a consequence of transmission (Markov and Pybus, 2015; Zinkernagel and Doherty, 1979; Borghans et al., 2004). If the viral epitope recognized by MHC-I maps to the viral genome at the same region, this could confer an increased viral fitness leading to mutation persistence or even the emergence of a new DRM in an ART-naïve host (Gatanaga et al., 2013). While this phenomenon has been reported for individual HIV mutation:HLA pairs, a systematic assessment of the impact of epitope escape across HIV DRM:HLA pairs in a representative population has not yet been reported.

In this study, we investigated and analyzed the viral and genetic data from ART-naïve patients in the Swiss HIV Cohort Study (SHCS). This is leveraging the unique combination of viral and human genetic data in the SHCS, with over 20,000 genotypic resistance tests and over 5000 patients with information on HLA-I alleles. This allowed us to systematically screen the cohort for associations between DRM:HLA-I pairs and hence for pairs where escape from HLA-I binding might confer the DRM an evolutionary advantage even in the absence of ART.

Materials and methods

Swiss HIV Cohort Study

Request a detailed protocol

The SHCS is a prospective multicenter study with continuing enrollment, aiming to include all people living with HIV in Switzerland since 1988. About half of all people living with HIV (PLWH) as notified to the Swiss health authorities are voluntarily participating in the SHCS, and include three-quarters of all PLWH receiving ART in the country (Schoeni-Affolter et al., 2010). As of August 2019, the SHCS has a cumulative total of 20,741 patients. Demographic information, mode of HIV transmission, treatment, clinical, and other data are updated every 6 months per standard protocol.

Drug resistance mutation data

Request a detailed protocol

The SHCS Drug Resistance Database contains the HIV sequence data, primarily partial pol gene sequences, used to determine the presence of DRMs in the viral genome (von Wyl et al., 2007). This data, currently covering 13,798 patients, was obtained from both routine clinical testing and systematic retroactive sequencing of stored plasma samples (Kletenkov et al., 2017; von Wyl et al., 2016). To reduce the scope of our systematic screening to only HIV mutations relevant to drug resistance (thus reducing the risk of overtesting), we only considered the presence of DRMs as defined by the Stanford Drug Resistance Database (Rhee et al., 2003). To avoid confounding by the effect of ART, we only considered sequences in ART-naïve individuals (before ART treatment).

HLA data

Request a detailed protocol

Data on the HLA class I type was available for 6453 SHCS patients. This information was obtained from SNP genotype data, using SNP2HLA with the type 1 Diabetes Genetics Consortium reference panel for HLA imputation techniques on the exome/SNP data (Jia et al., 2013; Szolek et al., 2014; Dilthey et al., 2016). We limited our analyses to that of the HLA class I (HLA-A, -B, and -C) considering the existing literature supporting the role of HLA class I peptides in HIV control (Leslie et al., 2010; Pereyra et al., 2010). Of these patients with HLA data, 3997 additionally had drug resistance testing data.

Screening candidate pairs of DRM:HLA-type

Request a detailed protocol

Our study aimed to retrieve all DRMs identified in the SHCS as well as the HLA-I types found, to analyze whether or not a specific HLA-I type significantly alters the probability of finding a DRM. As there were a possible 5561 combinations represented in our dataset, it was necessary to reduce these candidate pairs to only those for which our data provided sufficient statistical power to detect an association (Figure 1). To do this, we filtered out only the combinations where the number of SHCS patients with the given mutation or HLA type were sufficient to provide a statistical power of 0.8, assuming an odds ratio (OR) of 3. This resulted in 225 pairs, from which 225 logistic regression models were made. For each model, the duration of HIV infection time and the presence/absence of the queried HLA-I type were used as predictors of the outcome – the presence of the resistance mutation in the last available resistance test from a given patient when they were ART-naïve. We then used a Benjamini–Hochberg adjustment to account for multiple testing, considering a false discovery rate of 0.2. We purposefully used a more liberal false discovery rate and OR in the prior steps to avoid erroneously discarding any mutation:HLA pair with a potentially valid association, with the intent of compensating for this with the following three analyses assessing the plausibility of the identified pairs:

Figure 1
Download asset Open asset
Flowchart of methodology of obtaining the candidate DRM:HLA pairs with possible epitope relationship.

From the 3997 SHCS patients with both HLA-I data and drug resistance testing data, 5561 potential combinations of HLA-I type and DRMs were examinable, from which only 225 had sufficient power for testing. From these 225, three candidate pairs were found to have a significant HLA term in a logistic regression model predicting the resistance mutation in question. DRM, drug-resistant mutation; HLA, human leukocyte antigen.

  1. Testing if the impact of duration of HIV infection on the emergence of DRM of interest depends on HLA type: For each candidate pair identified and systematically filtered out after the initial screening, we created a multivariable logistic regression model, where the outcome is the presence of the mutation in the ART-naïve patients in their earliest available sequence (before the start of ART), with the predictors being the presence of the queried HLA type, duration of HIV infection until time of ART initiation, and additionally, an interaction term between HLA type and infection time. The purpose of the interaction term is to measure if the presence or absence of the queried HLA type affects the selection pressure on the resistance mutation, which would be determined by the interaction term with time since HIV infections – that is, a significant interaction term would imply that time since HIV infection has a different effect on the odds of observing the DRM depending on whether the HLA allele is present or not.

  2. Longitudinal/survival analyses: In addition to the cross-sectional logistic regression models, we used Cox proportional hazards survival models to test whether patients initially free of the queried DRM developed it over time. We only considered resistance testing data and time at risk before ART initiation. A patient requires at least two sequences before ART initiation to be included in this analysis. We observed which of the candidate DRM:HLA pairs yielded a survival model where the presence of the queried HLA type was significantly associated with a higher or lower hazard of developing/detecting the mutation over time.

  3. Mechanistic plausibility/epitopic binding: To examine whether there was any mechanistic plausibility to the associations found in the above analyses, we utilized the program server NetMHCpan 4.1 to predict the binding affinity of the HLA allele to the all 9-mer peptides including the mutation position, with either the wild-type amino acid at the position or one of the three most common mutated amino acids observed (Reynisson et al., 2020). For the candidate pairs where the mutation does cause immune escape, we would anticipate the binding to be stronger for the wild-type peptide compared to the mutated peptides. Additionally, we searched the Los Alamos HIV Molecular Immunology Database to corroborate the candidate pairs with prior experimental studies indicating the HLA–epitope match (Korber et al., 2021).

Software

All analyses (besides the epitope binding predictions performed with netMHCpan) were done in R (version 3.6.1). The code can be found in Github (Nguyen, 2021).

Results

Obtaining candidate HLA–mutation pairs

From the 20,741 patients in the SHCS, 3997 had both HLA-I alleles data and resistance testing data (Figure 1). Characteristics of these patients are shown in Table 1. Patients with HLA data were more likely to be Caucasian compared to the general SHCS population, as the HLA SNP imputation methods were validated on a Caucasian population. In the data set, there were 5561 different combinations of HLA-I types represented and DRMs. Only 225 of these pairs had sufficient diversity at the HLA and DRM positions to convey a power greater than 0.8 to detect a strong effect defined as OR = 3 (see 'Materials and methods'). Using logistic regression models, we found three DRM:HLA pairs after multiple testing adjustment (described in Supplementary file 1), with a significant impact of the queried HLA type on the odds of observing the DRM: RT-E138:HLA-B18 (OR 6.999, 95% CI 4.662–10.413), RT-E138:HLA-A24 (OR 2.444, 95% CI 1.602–3.658), and RT-V179:HLA-B35 (OR 2.431, 95% CI 1.398–4.108). All three combinations involved a DRM in the reverse transcriptase (RT) gene. Of the three combinations, two were with HLA-B, while one was with HLA-A. These three candidate pairs were further evaluated with three complementary methods: (1) a further cross-sectional analysis examining the presence of an interaction term between infection time and HLA type, (2) a longitudinal survival analysis examining time to the DRM detection among treatment-naïve patients initially without the queried DRM detectable, and (3) NetMHCPan MHC binding prediction analysis to examine mechanistic plausibility.

Table 1
General characteristics of SHCS patients and those with resistance mutation and human leukocyte antigen (HLA) data.

Overview of general characteristics of SHCS patients and the subsets with sequencing resistance testing data, HLA-I data, and both. IQR: interquartile range; MSM: men who have sex with men; HET: heterosexual; IDU: intravenous drug use.

All SHCS participantsSHCS patients with resistance testing dataSHCS patients with HLA-I dataSHCS patients with HLA-I and resistance testing data
Number20,74113,11664503997
Median age (IQR)56 (48–62)54 (47–60)55 (49–62)54 (47–60)
Male (%)15,064 (72.6%)9402 (71.2%)4836 (75.0%)3027 (75.7%)
Risk group:
MSM		8100 (39.1%)5226 (39.8%)2777 (43.1%)1784 (44.6%)
HET6841 (33.0%)4731 (36.1%)2173 (33.7%)1439 (36.0%)
IDU4840 (23.3%)2568 (19.6%)1255 (19.5%)620 (15.5%)
Other960 (4.6%)591 (4.5%)245 (3.8%)154 (3.9%)
White (%)14044 (67.7%)9993 (76.2%)5661 (87.8%)3487 (87.2%)

HLA-I types and DRMs in study population

The most commonly found HLA-I types are summarized in Table 2. Of note, 668 (16.7%) have an HLA-A24 allele, 376 (9.4%) with an HLA-B18 allele, and 728 (18.2%) with HLA-B35. Of the 3997 patients with both DRM and HLA-I data available, 719 (18.0%) had at least 1 DRM, of which 209 (5.2%) had multiple DRMs. Overall, 2267 of all 5155 DRMs in the study population are found among treatment-naïve individuals, and the most frequent of the 1072 DRMs found in the first resistance test in treatment-naïve individuals are summarized in Table 3. As for the two DRMs of interest, 145 had a DRM at RT-E138: 124 RT-E138A, 14 RT-E138G, 6 RT-E138K, and 1 RT-E138Q. Eighty-two were found at RT-V179: 68 RT-V179D, 13 RT-V179E, and 1 RT-V179F.

Table 2
Distribution of most common HLA-I A, B, and C alleles in study population.

Ten most common HLA-A, -B, and -C types in study population individuals with both HLA-I and DRM information. Frequency and percentage of individuals with each allele are indicated. DRM, drug-resistant mutation; HLA, human leukocyte antigen.

HLA-A typeFrequencyPercentage
02183846.0
0396424.1
0185721.4
2466816.7
1149312.3
683408.5
323027.6
303007.5
262726.8
292616.5
HLA-B typeFrequencyPercentage
4490522.6
0781420.4
3572918.2
5163916.0
1558214.6
0850012.5
4041010.3
183769.4
573288.2
272947.4
HLA-C typeFrequencyPercentage
07179444.9
0494123.5
0381220.3
0677219.3
1251012.8
0548512.1
0240110.0
163418.5
013288.2
153208.0
Table 3
Distribution of most common drug-resistant mutations (DRMs) in study population.

Ten most common DRMs from the earliest available resistance testing of the study population, with the frequency and percentage of each among the study population indicated. Specific amino acid mutations represented in the population are shown.

GeneSpecific DRMFrequencyPercentage
RT-E138AGKQ1453.63
RT-T215ACDEFILNSVY1323.30
RT-V106AIM952.38
RT-V179DEF822.05
RT-M41L721.80
PR-M46ILV471.18
RT-K103NS461.15
RT-K219ENQR340.85
RT-D67EGN340.85
RT-M184IV300.75

Cross-sectional analyses/logistic regression models

To examine the effect of having a given HLA-I allele on the presence of the DRM in question, we created for each candidate pair a logistic regression model predicting the presence of that specific DRM (at the earliest resistance testing), given the presence/absence of the queried HLA-I type. From the three candidate pairs, one resultant logistic regression model had a significant interaction term between presence of the queried HLA type and duration of HIV infection (Figure 2). For RT-E138:HLA-B18, duration of HIV infection (OR 0.918, 95% CI 0.862–0.971 [p-value=0.004]) and the HLA:time-to-DRM interaction term (OR 1.169, 95% CI 1.075–1.273 [p-value<0.001]) were both significant predictors of an RT-E138 mutation. Greater infection time was thus correlated with a smaller chance of having/detecting the RT-E138 mutation (due to the fitness cost of the mutation). However, in individuals with HLA-B18, the HLA:time-to-DRM interaction terms cause the selection pressure to reverse direction, hence greater infection time is instead correlated with a greater probability of an RT-E138 mutation for HLA-B18 individuals.

Figure 2
Download asset Open asset
Logistic regression models testing for interaction between the queried human leukocyte antigen (HLA) type and duration of infection in predicting the presence of drug-resistant mutation (DRM).

Of the three candidate DRM:HLA type pairs, one pair, RT-E138:HLA-B18, indicates a significant interaction term between the presence of the queried HLA type and the duration of HIV infection in a logistic regression model predicting the presence of a mutation at RT-E138 (A). (B) Details of all three candidates’ logistic regression models.

Longitudinal/survival analyses

To examine the effect of having a given HLA-I allele on the development of the DRM in question, we performed for each pair a survival analysis to observe how many individuals initially without the DRM eventually develop it prior to initiation of ART. Two of the three candidate DRM:HLA pairs were shown to have a significant difference in the probability of the queried mutation arising in initially wild-type individuals. For RT-E138:HLA-B18, 63 (7.7%) of the 813 patients without an RT-E138 mutation were HLA-B18, among which 5 (7.9%) developed it before ART initiation, compared to the 5 (0.7%) of the 750 with another HLA-B18 type (hazard ratio [HR] 12.211, 95% CI 3.523–42.318 [p-value<0.001]) (Figure 3). RT-V179:HLA-B35 showed a similarly sharpened increased hazard of developing the mutation. Of the 150 (18.3%) of the 821 patients with HLA-B35 (initially without an HLA-B35 mutation), 3 (2.0%) developed a mutation at RT-V179, compared to only 1 (0.1%) of the 671 with another HLA-B type (HR 16.116, 95% CI 1.673–155.216 [p-value=0.016]).

Figure 3
Download asset Open asset
Hazard ratios and cumulative hazards of developing queried drug-resistant mutation over time in relation to the presence of human leukocyte antigen (HLA) type.

(A) Cox proportional hazard ratios for developing the queried drug-resistant mutation with the queried HLA-I type. (B, C) Cumulative hazard plots of the two pairs from (A) where the hazard ratios were significant, indicating cumulative hazards of developing the mutation among those initially wild type, with red lines indicating individuals with the queried HLA type and blue lines for those with another HLA type.

Mechanistic plausibility/epitope binding

NetMHCpan predictions of HLA binding were performed to gauge the mechanistic plausibility of the effects observed in the first two analyses. These also indicated weakened HLA binding to the DRM-peptide (i.e. supporting the putative association) for two of the three candidate pairs: RT-E138:HLA-B18 and RT-V179:HLA-B35 (Supplementary file 2). Thus, in these two DRM:HLA pairs, the HLA-I allele is driving viral immune escape by reducing avidity to MHC. The two pairs supported by mechanistic plausibility are the same two pairs having a significant relationship between HLA type presence and survival in the longitudinal analyses (Table 4). Prior literature indicating experimentally verified epitope binding of the HIV proteome to HLA also exists for these two pairs (Gatanaga et al., 2013; Kopycinski et al., 2014; Liu et al., 2006; Li et al., 2011; Llano et al., 2019; Pereyra et al., 2014; Kiepiela et al., 2007; Peretz et al., 2011; Rowland-Jones et al., 1995; Tebit et al., 2009; Bond et al., 2001).

Table 4
DRM:HLA pairs corroborated by each analytical approach.

Summary of HLA–drug-resistant mutation pairs in all three approaches. Methods that corroborate the HLA–mutation relationship are indicated by ‘yes.’ DRM, drug-resistant mutation; HLA, human leukocyte antigen.

DRM:HLA pairInteraction term in
cross-sectional logistic regression		Longitudinal/
survival analysis		Mechanistic plausibility
RT-E138:HLA-B18YesYesYes
RT-E138:HLA-A24NoNoNo
RT-V179:HLA-B35NoYesYes

Discussion

Our analyses indicate strong evidence for the presence of an evolutionary intrapatient interaction between HIV DRMs and certain HLA-I alleles. Of the three candidate DRM:HLA pairs analyzed by three methods, two were supported by two of the analyses to show this relationship, of which one, RT-E138:HLA-B18, was supported by all three (Table 4). This is notable as this pair has been specifically investigated by Gatanaga et al., 2013, who showed both experimentally and through structural modeling that HLA B18-restricted CTLs select for a mutation in RT138. Our study independently demonstrates that this interaction is relevant at the population level, both in cross-sectional and in longitudinal cohort data. Of note, both DRMs are associated with the nonnucleoside analogue reverse transcriptase inhibitor class of ART drugs, with RT-V179D/F/T being associated with resistance to Etravirine and RT-V179L being associated with Rilpivirine. RT-E138A/G/K/Q is associated with resistance to Etravirine and Rilpivirine (International Antiviral Society, 2019). Estimates of virological failure for these two drugs are upwards of 5% and 11%, for Efavirenz and Rilpivirine, respectively (Sanford, 2012).

These results have major implications for our understanding of the evolutionary epidemiology in viral infections as they demonstrate a considerable interaction between the processes of drug resistance evolution and immune escape observed for several drug classes and HLA alleles in a representative patient population. This extends the standard paradigm that resistance mutations are acquired in treated individuals, may become transmitted, but eventually disappear in treated individuals with the possibility that resistance mutations newly emerge in untreated individuals due to immune escape. While this mechanism does obviously not account for the majority of DRMs in patients with untreated HIV, it may not be a negligible phenomenon.

In fact, HLA type-driven viral evolution in DRM-relevant CTL epitopes may be particularly relevant in light of the estimated 10% with a DRM in ART-naïve European HIV-positive patients, and even higher figures in low-resource settings, where continuing issues with access to treatment and adherence exacerbate the risk of treatment failure (Günthard et al., 2019; Hofstra et al., 2016; Wittkop et al., 2011; Chimukangara et al., 2019; Pessôa and Sanabani, 2017). As HLA is extremely diverse in the human population, and exhibits high variation in allelic frequency in different geographic regions (Piazza et al., 1980), this DRM:HLA link may partially explain regional variations in pre-treatment drug resistance. Accordingly, we would expect the emergence of certain DRMs in the population that is ART-naïve, or specifically, naïve to Etravirine and Rilpivirine, if the local population has a higher prevalence of the HLA types indicated in our analyses.

As the SHCS primarily consists of individuals of white ethnicity from Switzerland and surrounding countries, our study is statistically best powered to detect DRM:HLA pairs amongst white patients, and may be too underpowered to detect DRM:HLA pairs involving HLA-I alleles more prevalent in non-white, low-resource settings – precisely where DRMs are a more urgent issue. This is even concerning considering the high number of pairs eliminated after filtering out those with insufficient numbers to power an analysis (Figure 1). This lack of power may explain, for example, RT-V179:HLA-B35 indicates a DRM:HLA association in the longitudinal analysis, but not in the cross-sectional analysis with the interaction term (Table 4). It is conceivable that with greater numbers of patients and more years of follow-up that more DRM:HLA pairs would be detected and that these inter-analyses inconsistencies would be resolved, though we should not exclude the possibility of other sources for such discrepancies, for example, imprecise estimates of HIV infection time. The limitation of most sequences to the pol gene also made the analyses underpowered to find DRM:HLA relationships in other genes.

Despite these limitations, our study is strengthened by its methodological breadth and thoroughness. While other studies have examined the link between HLA-I and DRMs (Ahlenstiel et al., 2007; Bailey et al., 2007), this study is on a numerically larger scale, and is unique to systematically examine an entire HIV cohort population’s DRM profiles and HLA-I types to screen for potential DRM:HLA pairs. As the cross-sectional analysis took into account duration of infection, it thus effectively excluded from consideration tDRMs that were disadvantageous to viral fitness in ART-naïve patients, identifying any DRMs that remained over time despite the lack of selection pressure from ART, thus mitigating the possibility that these DRMs are merely tDRMs with no relevance to viral pathogenesis in the patient. Additionally, as it is now clinical practice to immediately initiate ART in newly diagnosed patients since several years, there is now hardly ever more than one ART-naïve sequence per patient, thus making our longitudinal analysis very unique and difficult to replicate in the future (World Health Organization, 2016; Ryom et al., 2016).

By utilizing three different analytical approaches, especially by combining the longitudinal and cross-sectional approaches, we are able to identity and validate DRM:HLA pairs where there is this epitope–mutation interaction. The NetMHCPan analyses allowed us to connect the associations we statistically detected at a population level with predicted MHC binding, which was additionally supported by prior experimental findings. This screening process is also strengthened by the restriction to pairs where the HLA-I and DRM frequencies have sufficient power, thus reducing the number of performed tests and the magnitude of the Benjamini–Hochberg multiple testing adjustment.

Our findings not only have an impact on our understanding of why DRMs tend to be transmitted and maintained in certain individuals, but may also help inform ART in the future. While it would not be feasible to tailor ART treatment based on personal HLA genotyping in resource-limited settings, this information could be used to help anticipate a higher frequency of certain DRMs where a corresponding HLA-I type is more prevalent. As HIV sequencing progresses, more complete DRM:HLA data on other genes, particularly integrase, will become available at sufficiently powered frequencies, enabling us to detect potential DRM:HLA pairs that may affect the efficacy of integrase inhibitors, a newer and increasingly used ART drug class.

Data availability

The individual-level datasets generated and analyzed for the current study do not fullfill the requirements for open data access: (1) The SHCS informed consent states that sharing data outside the SHCS network is only permitted for specific studies on HIV infection and its related complications, and to researchers who have signed an agreement detailing the use of the data and biological samples; and (2) the data is too dense and comprehensive to preserve patient privacy in persons living with HIV. Per Swiss law, data cannot be shared if data subjects have not agreed or if data is too sensitive to share. Investigators with a request for the data that support the findings of this study should contact the corresponding author Roger Kouyos and the Scientific Board of the SHCS. The provision of data will be considered by the Scientific Board of the SHCS and the study team and is subject to Swiss legal and ethical regulations, and is outlined in a material and data transfer agreement. We have however, provided the data files (with the rows anonymized and randomly re-assorted) with the bare minimum number of variables necessary to do the core analyses and to assemble the figures as shown in the manuscript. The code for the analysis can be found on Github repository: https://github.com/hnyhnyhny/HNGUYEN_HLA_DRM (copy archived at https://archive.softwareheritage.org/swh:1:rev:4a03919f07748ff22c4bf529100505ecc78b57cd).

References

  8. Report
    1. Fund G
    (2019)
    HIV Drug Resistance Report 2019
    World Health Organization.
    1. Hofstra LM
    2. Sauvageot N
    3. Albert J
    4. Alexiev I
    5. Garcia F
    6. Struck D
    7. Van de Vijver D
    8. Åsjö B
    9. Beshkov D
    10. Coughlan S
    11. Descamps D
    12. Griskevicius A
    13. Hamouda O
    14. Horban A
    15. Van Kasteren M
    16. Kolupajeva T
    17. Kostrikis LG
    18. Liitsola K
    19. Linka M
    20. Mor O
    21. Nielsen C
    22. Otelea D
    23. Paraskevis D
    24. Paredes R
    25. Poljak M
    26. Puchhammer-Stöckl E
    27. Sönnerborg A
    28. Staneková D
    29. Stanojevic M
    30. Van Laethem K
    31. Zazzi M
    32. Zidovec Lepej S
    33. Boucher CAB
    34. Schmit JC
    35. Wensing AMJ
    36. Puchhammer-Stockl E
    37. Sarcletti M
    38. Schmied B
    39. Geit M
    40. Balluch G
    41. Vandamme AM
    42. Vercauteren J
    43. Derdelinckx I
    44. Sasse A
    45. Bogaert M
    46. Ceunen H
    47. De Roo A
    48. De Wit S
    49. Echahidi F
    50. Fransen K
    51. Goffard JC
    52. Goubau P
    53. Goudeseune E
    54. Yombi JC
    55. Lacor P
    56. Liesnard C
    57. Moutschen M
    58. Pierard D
    59. Rens R
    60. Schrooten Y
    61. Vaira D
    62. Vandekerckhove LPR
    63. Van den Heuvel A
    64. Van Der Gucht B
    65. Van Ranst M
    66. Van Wijngaerden E
    67. Vandercam B
    68. Vekemans M
    69. Verhofstede C
    70. Clumeck N
    71. Van Laethem K
    72. Beshkov D
    73. Alexiev I
    74. Lepej SZ
    75. Begovac J
    76. Kostrikis L
    77. Demetriades I
    78. Kousiappa I
    79. Demetriou V
    80. Hezka J
    81. Linka M
    82. Maly M
    83. Machala L
    84. Nielsen C
    85. Jørgensen LB
    86. Gerstoft J
    87. Mathiesen L
    88. Pedersen C
    89. Nielsen H
    90. Laursen A
    91. Kvinesdal B
    92. Liitsola K
    93. Ristola M
    94. Suni J
    95. Sutinen J
    96. Descamps D
    97. Assoumou L
    98. Castor G
    99. Grude M
    100. Flandre P
    101. Storto A
    102. Hamouda O
    103. Kücherer C
    104. Berg T
    105. Braun P
    106. Poggensee G
    107. Däumer M
    108. Eberle J
    109. Heiken H
    110. Kaiser R
    111. Knechten H
    112. Korn K
    113. Müller H
    114. Neifer S
    115. Schmidt B
    116. Walter H
    117. Gunsenheimer-Bartmeyer B
    118. Harrer T
    119. Paraskevis D
    120. Hatzakis A
    121. Zavitsanou A
    122. Vassilakis A
    123. Lazanas M
    124. Chini M
    125. Lioni A
    126. Sakka V
    127. Kourkounti S
    128. Paparizos V
    129. Antoniadou A
    130. Papadopoulos A
    131. Poulakou G
    132. Katsarolis I
    133. Protopapas K
    134. Chryssos G
    135. Drimis S
    136. Gargalianos P
    137. Xylomenos G
    138. Lourida G
    139. Psichogiou M
    140. Daikos GL
    141. Sipsas NV
    142. Kontos A
    143. Gamaletsou MN
    144. Koratzanis G
    145. Sambatakou H
    146. Mariolis H
    147. Skoutelis A
    148. Papastamopoulos V
    149. Georgiou O
    150. Panagopoulos P
    151. Maltezos E
    152. Coughlan S
    153. De Gascun C
    154. Byrne C
    155. Duffy M
    156. Bergin C
    157. Reidy D
    158. Farrell G
    159. Lambert J
    160. O'Connor E
    161. Rochford A
    162. Low J
    163. Coakely P
    164. O'Dea S
    165. Hall W
    166. Mor O
    167. Levi I
    168. Chemtob D
    169. Grossman Z
    170. Zazzi M
    171. de Luca A
    172. Balotta C
    173. Riva C
    174. Mussini C
    175. Caramma I
    176. Capetti A
    177. Colombo MC
    178. Rossi C
    179. Prati F
    180. Tramuto F
    181. Vitale F
    182. Ciccozzi M
    183. Angarano G
    184. Rezza G
    185. Kolupajeva T
    186. Vasins O
    187. Griskevicius A
    188. Lipnickiene V
    189. Schmit JC
    190. Struck D
    191. Sauvageot N
    192. Hemmer R
    193. Arendt V
    194. Michaux C
    195. Staub T
    196. Sequin-Devaux C
    197. Wensing AMJ
    198. Boucher CAB
    199. van de Vijver D
    200. van Kessel A
    201. van Bentum PHM
    202. Brinkman K
    203. Connell BJ
    204. van der Ende ME
    205. Hoepelman IM
    206. van Kasteren M
    207. Kuipers M
    208. Langebeek N
    209. Richter C
    210. Santegoets R
    211. Schrijnders-Gudde L
    212. Schuurman R
    213. van de Ven BJM
    214. Åsjö B
    215. Kran AB
    216. Ormaasen V
    217. Aavitsland P
    218. Horban A
    219. Stanczak JJ
    220. Stanczak GP
    221. Firlag-Burkacka E
    222. Wiercinska-Drapalo A
    223. Jablonowska E
    224. Maolepsza E
    225. Leszczyszyn-Pynka M
    226. Szata W
    227. Camacho R
    228. Palma C
    229. Borges F
    230. Paixão T
    231. Duque V
    232. Araújo F
    233. Otelea D
    234. Paraschiv S
    235. Tudor AM
    236. Cernat R
    237. Chiriac C
    238. Dumitrescu F
    239. Prisecariu LJ
    240. Stanojevic M
    241. Jevtovic D
    242. Salemovic D
    243. Stanekova D
    244. Habekova M
    245. Chabadová Z
    246. Drobkova T
    247. Bukovinova P
    248. Shunnar A
    249. Truska P
    250. Poljak M
    251. Lunar M
    252. Babic D
    253. Tomazic J
    254. Vidmar L
    255. Vovko T
    256. Karner P
    257. Garcia F
    258. Paredes R
    259. Monge S
    260. Moreno S
    261. Del Amo J
    262. Asensi V
    263. Sirvent JL
    264. de Mendoza C
    265. Delgado R
    266. Gutiérrez F
    267. Berenguer J
    268. Garcia-Bujalance S
    269. Stella N
    270. de Los Santos I
    271. Blanco JR
    272. Dalmau D
    273. Rivero M
    274. Segura F
    275. Elías MJP
    276. Alvarez M
    277. Chueca N
    278. Rodríguez-Martín C
    279. Vidal C
    280. Palomares JC
    281. Viciana I
    282. Viciana P
    283. Cordoba J
    284. Aguilera A
    285. Domingo P
    286. Galindo MJ
    287. Miralles C
    288. Del Pozo MA
    289. Ribera E
    290. Iribarren JA
    291. Ruiz L
    292. de la Torre J
    293. Vidal F
    294. Clotet B
    295. Albert J
    296. Heidarian A
    297. Aperia-Peipke K
    298. Axelsson M
    299. Mild M
    300. Karlsson A
    301. Sönnerborg A
    302. Thalme A
    303. Navér L
    304. Bratt G
    305. Karlsson A
    306. Blaxhult A
    307. Gisslén M
    308. Svennerholm B
    309. Bergbrant I
    310. Björkman P
    311. Säll C
    312. Mellgren Å
    313. Lindholm A
    314. Kuylenstierna N
    315. Montelius R
    316. Azimi F
    317. Johansson B
    318. Carlsson M
    319. Johansson E
    320. Ljungberg B
    321. Ekvall H
    322. Strand A
    323. Mäkitalo S
    324. Öberg S
    325. Holmblad P
    326. Höfer M
    327. Holmberg H
    328. Josefson P
    329. Ryding U
    330. SPREAD Program
    (2016) Transmission of HIV drug resistance and the predicted effect on current First-line regimens in Europe
    Clinical Infectious Diseases 62:655–663.
    https://doi.org/10.1093/cid/civ963
  14. Book
    1. International Antiviral Society
    (2019)
    Update of the Drug Resistance Mutations in HIV-1
    USA: International Antiviral Society.
  19. Report
    1. Korber B
    2. Brander C
    3. Haynes BF
    4. Moore JP
    5. Koup R
    6. Walker BD
    7. Watkins DI
    (2021)
    HIV Molecular Immunology Database
    Los Alamos National Laboratory, Theoretical Biology and Biophysics.
  26. Book
    1. Llano A
    2. Cedeño S
    3. Arrieta SS
    4. Brander C
    (2019)
    Optimal HIV CTL epitopes update: Growing diversity in epitope length and HLA restriction
    Los Alamos, NM, USA: HIV Immunology and HIV/SIV Vaccine Databases; Los Alamos National Laboratory, Theoretical Biology and Biophysics.
    1. Pereyra F
    2. Jia X
    3. McLaren PJ
    4. Telenti A
    5. de Bakker PI
    6. Walker BD
    7. Ripke S
    8. Brumme CJ
    9. Pulit SL
    10. Carrington M
    11. Kadie CM
    12. Carlson JM
    13. Heckerman D
    14. Graham RR
    15. Plenge RM
    16. Deeks SG
    17. Gianniny L
    18. Crawford G
    19. Sullivan J
    20. Gonzalez E
    21. Davies L
    22. Camargo A
    23. Moore JM
    24. Beattie N
    25. Gupta S
    26. Crenshaw A
    27. Burtt NP
    28. Guiducci C
    29. Gupta N
    30. Gao X
    31. Qi Y
    32. Yuki Y
    33. Piechocka-Trocha A
    34. Cutrell E
    35. Rosenberg R
    36. Moss KL
    37. Lemay P
    38. O'Leary J
    39. Schaefer T
    40. Verma P
    41. Toth I
    42. Block B
    43. Baker B
    44. Rothchild A
    45. Lian J
    46. Proudfoot J
    47. Alvino DM
    48. Vine S
    49. Addo MM
    50. Allen TM
    51. Altfeld M
    52. Henn MR
    53. Le Gall S
    54. Streeck H
    55. Haas DW
    56. Kuritzkes DR
    57. Robbins GK
    58. Shafer RW
    59. Gulick RM
    60. Shikuma CM
    61. Haubrich R
    62. Riddler S
    63. Sax PE
    64. Daar ES
    65. Ribaudo HJ
    66. Agan B
    67. Agarwal S
    68. Ahern RL
    69. Allen BL
    70. Altidor S
    71. Altschuler EL
    72. Ambardar S
    73. Anastos K
    74. Anderson B
    75. Anderson V
    76. Andrady U
    77. Antoniskis D
    78. Bangsberg D
    79. Barbaro D
    80. Barrie W
    81. Bartczak J
    82. Barton S
    83. Basden P
    84. Basgoz N
    85. Bazner S
    86. Bellos NC
    87. Benson AM
    88. Berger J
    89. Bernard NF
    90. Bernard AM
    91. Birch C
    92. Bodner SJ
    93. Bolan RK
    94. Boudreaux ET
    95. Bradley M
    96. Braun JF
    97. Brndjar JE
    98. Brown SJ
    99. Brown K
    100. Brown ST
    101. Burack J
    102. Bush LM
    103. Cafaro V
    104. Campbell O
    105. Campbell J
    106. Carlson RH
    107. Carmichael JK
    108. Casey KK
    109. Cavacuiti C
    110. Celestin G
    111. Chambers ST
    112. Chez N
    113. Chirch LM
    114. Cimoch PJ
    115. Cohen D
    116. Cohn LE
    117. Conway B
    118. Cooper DA
    119. Cornelson B
    120. Cox DT
    121. Cristofano MV
    122. Cuchural G
    123. Czartoski JL
    124. Dahman JM
    125. Daly JS
    126. Davis BT
    127. Davis K
    128. Davod SM
    129. DeJesus E
    130. Dietz CA
    131. Dunham E
    132. Dunn ME
    133. Ellerin TB
    134. Eron JJ
    135. Fangman JJ
    136. Farel CE
    137. Ferlazzo H
    138. Fidler S
    139. Fleenor-Ford A
    140. Frankel R
    141. Freedberg KA
    142. French NK
    143. Fuchs JD
    144. Fuller JD
    145. Gaberman J
    146. Gallant JE
    147. Gandhi RT
    148. Garcia E
    149. Garmon D
    150. Gathe JC
    151. Gaultier CR
    152. Gebre W
    153. Gilman FD
    154. Gilson I
    155. Goepfert PA
    156. Gottlieb MS
    157. Goulston C
    158. Groger RK
    159. Gurley TD
    160. Haber S
    161. Hardwicke R
    162. Hardy WD
    163. Harrigan PR
    164. Hawkins TN
    165. Heath S
    166. Hecht FM
    167. Henry WK
    168. Hladek M
    169. Hoffman RP
    170. Horton JM
    171. Hsu RK
    172. Huhn GD
    173. Hunt P
    174. Hupert MJ
    175. Illeman ML
    176. Jaeger H
    177. Jellinger RM
    178. John M
    179. Johnson JA
    180. Johnson KL
    181. Johnson H
    182. Johnson K
    183. Joly J
    184. Jordan WC
    185. Kauffman CA
    186. Khanlou H
    187. Killian RK
    188. Kim AY
    189. Kim DD
    190. Kinder CA
    191. Kirchner JT
    192. Kogelman L
    193. Kojic EM
    194. Korthuis PT
    195. Kurisu W
    196. Kwon DS
    197. LaMar M
    198. Lampiris H
    199. Lanzafame M
    200. Lederman MM
    201. Lee DM
    202. Lee JM
    203. Lee MJ
    204. Lee ET
    205. Lemoine J
    206. Levy JA
    207. Llibre JM
    208. Liguori MA
    209. Little SJ
    210. Liu AY
    211. Lopez AJ
    212. Loutfy MR
    213. Loy D
    214. Mohammed DY
    215. Man A
    216. Mansour MK
    217. Marconi VC
    218. Markowitz M
    219. Marques R
    220. Martin JN
    221. Martin HL
    222. Mayer KH
    223. McElrath MJ
    224. McGhee TA
    225. McGovern BH
    226. McGowan K
    227. McIntyre D
    228. Mcleod GX
    229. Menezes P
    230. Mesa G
    231. Metroka CE
    232. Meyer-Olson D
    233. Miller AO
    234. Montgomery K
    235. Mounzer KC
    236. Nagami EH
    237. Nagin I
    238. Nahass RG
    239. Nelson MO
    240. Nielsen C
    241. Norene DL
    242. O'Connor DH
    243. Ojikutu BO
    244. Okulicz J
    245. Oladehin OO
    246. Oldfield EC
    247. Olender SA
    248. Ostrowski M
    249. Owen WF
    250. Pae E
    251. Parsonnet J
    252. Pavlatos AM
    253. Perlmutter AM
    254. Pierce MN
    255. Pincus JM
    256. Pisani L
    257. Price LJ
    258. Proia L
    259. Prokesch RC
    260. Pujet HC
    261. Ramgopal M
    262. Rathod A
    263. Rausch M
    264. Ravishankar J
    265. Rhame FS
    266. Richards CS
    267. Richman DD
    268. Rodes B
    269. Rodriguez M
    270. Rose RC
    271. Rosenberg ES
    272. Rosenthal D
    273. Ross PE
    274. Rubin DS
    275. Rumbaugh E
    276. Saenz L
    277. Salvaggio MR
    278. Sanchez WC
    279. Sanjana VM
    280. Santiago S
    281. Schmidt W
    282. Schuitemaker H
    283. Sestak PM
    284. Shalit P
    285. Shay W
    286. Shirvani VN
    287. Silebi VI
    288. Sizemore JM
    289. Skolnik PR
    290. Sokol-Anderson M
    291. Sosman JM
    292. Stabile P
    293. Stapleton JT
    294. Starrett S
    295. Stein F
    296. Stellbrink HJ
    297. Sterman FL
    298. Stone VE
    299. Stone DR
    300. Tambussi G
    301. Taplitz RA
    302. Tedaldi EM
    303. Telenti A
    304. Theisen W
    305. Torres R
    306. Tosiello L
    307. Tremblay C
    308. Tribble MA
    309. Trinh PD
    310. Tsao A
    311. Ueda P
    312. Vaccaro A
    313. Valadas E
    314. Vanig TJ
    315. Vecino I
    316. Vega VM
    317. Veikley W
    318. Wade BH
    319. Walworth C
    320. Wanidworanun C
    321. Ward DJ
    322. Warner DA
    323. Weber RD
    324. Webster D
    325. Weis S
    326. Wheeler DA
    327. White DJ
    328. Wilkins E
    329. Winston A
    330. Wlodaver CG
    331. van't Wout A
    332. Wright DP
    333. Yang OO
    334. Yurdin DL
    335. Zabukovic BW
    336. Zachary KC
    337. Zeeman B
    338. Zhao M
    339. International HIV Controllers Study
    (2010) The major genetic determinants of HIV-1 control affect HLA class I peptide presentation
    Science 330:1551–1557.
    https://doi.org/10.1126/science.1195271
  45. Book
    1. World Health Organization
    (2016)
    Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach
    World Health Organization.

Article and author information

Author details

  1. Huyen Nguyen

    1. Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
    2. Institute of Medical Virology, Swiss National Center for Retroviruses, University of Zurich, Zurich, Switzerland
    Contribution
    Conceptualization, Software, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing - original draft, Writing - review and editing
    For correspondence
    Huyen.Nguyen@usz.ch
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1486-8970

  2. Christian Wandell Thorball

    1. School of Life Sciences, École Polytechnique, Fédérale de Lausanne, Switzerland
    2. Precision Medicine Unit, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
    Contribution
    Resources, Data curation, Software, Validation, Writing - review and editing
    Competing interests
    No competing interests declared

  3. Jacques Fellay

    1. School of Life Sciences, École Polytechnique, Fédérale de Lausanne, Switzerland
    2. Precision Medicine Unit, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
    Contribution
    Resources, Data curation, Supervision, Methodology, Writing - review and editing
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8240-939X

  4. Jürg Böni

    Institute of Medical Virology, Swiss National Center for Retroviruses, University of Zurich, Zurich, Switzerland
    Contribution
    Resources, Data curation, Writing - review and editing
    Competing interests
    No competing interests declared

  5. Sabine Yerly

    Laboratory of Virology, Geneva University Hospital, University of Geneva, Geneva, Switzerland
    Contribution
    Resources, Data curation, Writing - review and editing
    Competing interests
    No competing interests declared

  6. Matthieu Perreau

    Division of Immunology and Allergy, University Hospital Lausanne, University of Lausanne, Lausanne, Switzerland
    Contribution
    Resources, Data curation, Writing - review and editing
    Competing interests
    No competing interests declared

  7. Hans H Hirsch

    1. Transplantation & Clinical Virology, Department of Biomedicine, University of Basel, Basel, Switzerland
    2. Infectious Diseases and Hospital Epidemiology, Department of Medicine, University Hospital Basel, Basel, Switzerland
    3. Clinical Virology, Laboratory Medicine, University Hospital Basel, Basel, Switzerland
    Contribution
    Resources, Data curation, Writing - review and editing
    Competing interests
    No competing interests declared

  8. Katharina Kusejko

    1. Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
    2. Institute of Medical Virology, Swiss National Center for Retroviruses, University of Zurich, Zurich, Switzerland
    Contribution
    Software, Supervision, Writing - review and editing
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4638-1940

  9. Maria Christine Thurnheer

    University Clinic of Infectious Diseases, University Hospital of Bern, University of Bern, Bern, Switzerland
    Contribution
    Resources, Data curation, Writing - review and editing
    Competing interests
    No competing interests declared

  10. Manuel Battegay

    Infectious Diseases and Hospital Epidemiology, Department of Medicine, University Hospital Basel, Basel, Switzerland
    Contribution
    Resources, Data curation, Writing - review and editing
    Competing interests
    No competing interests declared

  11. Matthias Cavassini

    Department of Infectious Diseases, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland
    Contribution
    Resources, Data curation, Writing - review and editing
    Competing interests
    has received research and travel grants for his institution from ViiV and Gilead.

  12. Christian R Kahlert

    Division of Infectious Diseases and Hospital Epidemiology, Kantonsspital St. Gallen, St. Gallen, Switzerland
    Contribution
    Resources, Data curation, Writing - review and editing
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-0784-3276

  13. Enos Bernasconi

    Division of Infectious Diseases, Regional Hospital, Lugano, Switzerland
    Contribution
    Resources, Data curation, Writing - review and editing
    Competing interests
    has received fees for his institution for participation to advisory board from MSD, Gilead Sciences, ViiV Healthcare, Abbvie and Janssen.

  14. Huldrych F Günthard

    1. Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
    2. Institute of Medical Virology, Swiss National Center for Retroviruses, University of Zurich, Zurich, Switzerland
    Contribution
    Resources, Data curation, Supervision, Funding acquisition, Methodology, Project administration, Writing - review and editing
    Competing interests
    HFG has received unrestricted research grants from Gilead Sciences and Roche; fees for data and safety monitoring board membership from Merck; consulting/advisory board membership fees from Gilead Sciences, Sandoz and Mepha; and travel reimbursement from Gilead.

  15. Roger D Kouyos

    1. Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
    2. Institute of Medical Virology, Swiss National Center for Retroviruses, University of Zurich, Zurich, Switzerland
    Contribution
    Conceptualization, Software, Supervision, Funding acquisition, Methodology, Project administration, Writing - review and editing
    For correspondence
    roger.kouyos@usz.ch
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9220-8348

  16. The Swiss HIV Cohort Study

    Contribution
    Conceptualization, Software, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing - original draft, Writing - review and editing

Funding

University of Zurich (University Research Priority Program, “Evolution in Action: From Genomes to Ecosystems”: U-702-26-01)

  • Huyen Nguyen
  • Roger D Kouyos

Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (BSSGI0_155851)

  • Huldrych F Günthard

Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (179571)

  • Huldrych F Günthard

Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (148522)

  • Huldrych F Günthard

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Acknowledgements

The authors thank the patients who participated in the Swiss HIV Cohort Study; the physicians and study nurses, for the excellent patient care provided to participants; the resistance laboratories for high-quality genotyping drug resistance testing; SmartGene (Zug, Switzerland), for technical support; Alexandra Scherrer, Susanne Wild, and Anna Traytel from the SHCS data center for data management; and Marianne Amstutz, Danièle Perraudin, and Mirjam Minichiello for administration. The members of the Swiss HIV Cohort Study include the following: A Anagnostopoulos, MB, EB, JB, D L Braun, H C Bucher, A Calmy, MC, A Ciuffi, G Dollenmaier, M Egger, L Elzi, J Fehr, JF, H Furrer (chairman of the Clinical and Laboratory Committee), C A Fux, H F Günthard (president of the SHCS), D Haerry (deputy of ‘Positive Council’), B Hasse, HH Hirsch, M Hoffmann, I Hösli, M Huber, C Kahlert, L Kaiser, O Keiser, TK, RD Kouyos, H Kovari, B Ledergerber, G Martinetti, B Martinez de Tejada, C Marzolini, KJ Metzner, N Müller, D Nicca, PP, G Pantaleo, MP, A Rauch (chairman of the Scientific Board), C Rudin (chairman of the Mother and Child Substudy), K Kusejko (head of Data Center), P Schmid, R Speck, M Stöckle, P Tarr, A Trkola, PV, G Wandeler, R Weber, and SY.

Ethics

Human subjects: The SHCS has been approved by the participating institutions' ethics committees (Kantonale Ethikkommission Bern, Ethikkommission des Kantons St. Gallen, Comité; Départemental dÉthique des Spécialités Médicales et de Médecine Communautaire et de Premier Recours, Kantonale Ethikkommission Zurich, Repubblica e Cantone Ticino-Comitato Etico Cantonale, Commission Cantonale d'Éthique de la Recherche sur l'tre Humain, Ethikkommission beider Basel; all approvals are available at http://www.shcs.ch/206-%0Dethic-committee-approval-and-informed-consent). Written informed consent was obtained from all participants.

Version history

  1. Received: February 9, 2021
  2. Accepted: May 18, 2021
  3. Version of Record published: June 1, 2021 (version 1)

Copyright

© 2021, Nguyen et al.

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 467
    views
  • 45
    downloads
  • 3
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Huyen Nguyen
  2. Christian Wandell Thorball
  3. Jacques Fellay
  4. Jürg Böni
  5. Sabine Yerly
  6. Matthieu Perreau
  7. Hans H Hirsch
  8. Katharina Kusejko
  9. Maria Christine Thurnheer
  10. Manuel Battegay
  11. Matthias Cavassini
  12. Christian R Kahlert
  13. Enos Bernasconi
  14. Huldrych F Günthard
  15. Roger D Kouyos
  16. The Swiss HIV Cohort Study
(2021)
Systematic screening of viral and human genetic variation identifies antiretroviral resistance and immune escape link
eLife 10:e67388.
https://doi.org/10.7554/eLife.67388

Share this article

https://doi.org/10.7554/eLife.67388

Categories and tags

Research organism

Further reading

    1. Medicine
    2. Microbiology and Infectious Disease
    3. Epidemiology and Global Health
    4. Immunology and Inflammation

    Infectious Diseases: A Collection of Translational and Clinical Research Articles

    Edited by Jos WM van der Meer et al.
    Collection

    eLife has published articles on a wide range of infectious diseases, including COVID-19, influenza, tuberculosis, HIV/AIDS, malaria and typhoid fever.

    1. Epidemiology and Global Health

    A retrospective cohort study of Paxlovid efficacy depending on treatment time in hospitalized COVID-19 patients

    Zhanwei Du, Lin Wang ... Lauren A Meyers
    Short Report

    Paxlovid, a SARS-CoV-2 antiviral, not only prevents severe illness but also curtails viral shedding, lowering transmission risks from treated patients. By fitting a mathematical model of within-host Omicron viral dynamics to electronic health records data from 208 hospitalized patients in Hong Kong, we estimate that Paxlovid can inhibit over 90% of viral replication. However, its effectiveness critically depends on the timing of treatment. If treatment is initiated three days after symptoms first appear, we estimate a 17% chance of a post-treatment viral rebound and a 12% (95% CI: 0%-16%) reduction in overall infectiousness for non-rebound cases. Earlier treatment significantly elevates the risk of rebound without further reducing infectiousness, whereas starting beyond five days reduces its efficacy in curbing peak viral shedding. Among the 104 patients who received Paxlovid, 62% began treatment within an optimal three-to-five-day day window after symptoms appeared. Our findings indicate that broader global access to Paxlovid, coupled with appropriately timed treatment, can mitigate the severity and transmission of SARS-Cov-2.

    1. Epidemiology and Global Health

    Higher ratio of plasma omega-6/omega-3 fatty acids is associated with greater risk of all-cause, cancer, and cardiovascular mortality: A population-based cohort study in UK Biobank

    Yuchen Zhang, Yitang Sun ... Kaixiong Ye
    Research Article

    Background:

    Circulating omega-3 and omega-6 polyunsaturated fatty acids (PUFAs) have been associated with various chronic diseases and mortality, but results are conflicting. Few studies examined the role of omega-6/omega-3 ratio in mortality.

    Methods:

    We investigated plasma omega-3 and omega-6 PUFAs and their ratio in relation to all-cause and cause-specific mortality in a large prospective cohort, the UK Biobank. Of 85,425 participants who had complete information on circulating PUFAs, 6461 died during follow-up, including 2794 from cancer and 1668 from cardiovascular disease (CVD). Associations were estimated by multivariable Cox proportional hazards regression with adjustment for relevant risk factors.

    Results:

    Risk for all three mortality outcomes increased as the ratio of omega-6/omega-3 PUFAs increased (all Ptrend <0.05). Comparing the highest to the lowest quintiles, individuals had 26% (95% CI, 15–38%) higher total mortality, 14% (95% CI, 0–31%) higher cancer mortality, and 31% (95% CI, 10–55%) higher CVD mortality. Moreover, omega-3 and omega-6 PUFAs in plasma were all inversely associated with all-cause, cancer, and CVD mortality, with omega-3 showing stronger effects.

    Conclusions:

    Using a population-based cohort in UK Biobank, our study revealed a strong association between the ratio of circulating omega-6/omega-3 PUFAs and the risk of all-cause, cancer, and CVD mortality.

    Funding:

    Research reported in this publication was supported by the National Institute of General Medical Sciences of the National Institute of Health under the award number R35GM143060 (KY). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.